### **Overview** Orchid Pharma Limited (Orchid), established in 1992 as an Export Oriented Unit (EOU), is a vertically integrated Indian pharmaceutical company with capabilities spanning **research, API manufacturing, finished dosage formulations, and marketing**. The company specializes in **cephalosporin antibiotics** across all five generations and is a global leader in sterile cephalosporin production. Orchid operates one of only **three USFDA-approved sterile cephalosporin facilities worldwide**, and the **only Indian company to have discovered and developed a globally approved New Chemical Entity (NCE)** — **Enmetazobactam**. Acquired by the **Dhanuka Group** in April 2020 via the CIRP process, Orchid has undergone a strategic transformation to improve cost efficiency, strengthen R&D, and expand into high-value proprietary and hospital-focused anti-infective markets. The pending merger with **Dhanuka Laboratories** — expected to close in FY26 — aims to consolidate strengths and create a combined entity targeting **revenues of INR 1,500 crore and EBITDA of ~INR 175 crore**. --- ### **Strategic Highlight: Acquisition of Global Rights to Enmetazobactam (Exblifep)** In a landmark move, Orchid has **acquired 100% global rights to Enmetazobactam** and the trademark **Exblifep** by taking over the assets of **Allecra Therapeutics (Germany/France)** following its insolvency. This acquisition: - Makes Orchid the **sole Indian company to own a fully commercialized NCE** with approvals from **USFDA, EMA, and DCGI**. - Transfers **full regulatory and commercial control** of Enmetazobactam, enabling Orchid to directly monetize global royalties and out-license the molecule. - Allows Orchid to **retain previously paid double-digit royalties** from Advanz Pharma in Europe (now accruing directly to Orchid). - Positions **Exblifep (Cefepime + Enmetazobactam)** as a **blockbuster, carbapenem-sparing therapy** for multi-drug-resistant infections (cUTI, HAP, VAP, bacteremia), aligning with global antimicrobial resistance (AMR) priorities. --- ### **Commercial Momentum & Market Access** #### **1. Global & Domestic Launch of Exblifep / Orblicef** - **Exblifep** is already **licensed in Europe and MENA**, with **price approvals in major EU markets expected by end-FY25**, paving the way for commercialization. - In India, the brand **Orblicef** (same combination) is being co-marketed with **Cipla** since 2023, providing rapid hospital access across major chains (Apollo, Fortis, Max, Manipal). - Orblicef is **outperforming targets**, with **10–20% sequential monthly sales growth** and **over 200,000 vials sold** collectively by Orchid and Cipla to date. - Over **15,000 patients in India** have been treated with Enmetazobactam, demonstrating strong clinical acceptance. #### **2. Global Partnerships & Monetization Strategy** - Orchid is actively seeking **global out-licensing deals** for Exblifep ahead of potential U.S. entry. - The CEO estimates a **$250 million revenue potential** globally, with forecasts to be refined post licensing in fiscal year 2025–26. - The deal with **Advanz Pharma in Europe** remains binding; Orchid cannot renegotiate or exit, but now captures full royalty upside. --- ### **Key Growth Projects & Pipeline** 1. **7-ACA Project (Backward Integration)** - Critical for reducing China dependence on key cephalosporin intermediate. - Located in **Alathur (Chennai)** and **Jammu**, with land acquisition, technology transfer, and basic engineering complete. - All **fermenters erected**; major equipment installation underway. - **Mechanical completion** expected by **December 2026**, with **commercial launch by March 2027**. - Funded under the Indian **PLI Scheme**, expected to deliver **cost synergies and import substitution**. 2. **Cefiderocol Project** - Next-generation siderophore cephalosporin for multi-drug-resistant infections. - Production facility under construction; **building near completion, equipment delivery ongoing**. - Targeting **production readiness by Q4 2026**, **commercial launch in Q2 2027** (pending Indian regulatory approval). - Orchid has a **sublicensing agreement with Shionogi and GARDP** to supply the drug in 135 low- and middle-income countries. 3. **API & Formulation Expansion** - New **lyophilization** and **downstream processing facilities** under development. - Expansion of **sterile and oral API capacity** underway. - New **vial manufacturing facility** in pipeline. 4. **R&D & Innovation** - Focused on **cephalosporin chemistry**, **beta-lactamase inhibitors**, **peptide synthesis**, and **green chemistry**. - Plans to file **2–3 differentiated cephalosporin ANDAs** in the U.S. over the next 18 months. - R&D efforts aligned with **non-infringing (design-around) processes**, IP protection, and sustainable manufacturing (zero liquid discharge). --- ### **Domestic Expansion & Hospital Strategy** Orchid is aggressively targeting the **hospital critical care segment** in India: - The **Antimicrobial Stewardship (AMS) Division** is driving hospital engagement, **covering 120 key tertiary hospitals (10% market reach)**. - Targets **1,200 tertiary care hospitals** across India; aims to **secure annual tenders** in the next cycle. - AMS plays a critical role in **physician education, responsible antibiotic use**, and **commercial support** for future launches like Cefiderocol. - Expected to reach **breakeven within two years** of its October 2024 launch. --- ### **Financial & Operational Performance** - **API Business Dominance**: - **Oral APIs**: 421.33 MT sold in FY24–25 (₹6,469.8 crore revenue). - **Sterile APIs**: 154.94 MT sold (₹2,460.98 crore), up sharply YoY. - Revenue mix historically **60% unregulated markets (India, emerging)** and **40% regulated (U.S., Europe)**. - Volume growth of **18–20% YoY** in latest fiscal, though **pricing pressures** remain in antibiotics space. --- ### **Strategic Priorities (Nov 2025)** 1. **Monetize Exblifep** through global licensing deals ahead of U.S. market entry. 2. **Advance 7-ACA & Cefiderocol projects** on revised timelines. 3. **Expand hospital footprint** in India through AMS division. 4. **Maintain cost discipline** amid sector-wide pricing and demand pressures. 5. **Optimize capacity utilization** and reduce import dependency. 6. **Finalize Dhanuka Laboratories merger** to unlock scale and synergies.